Zebrafish bioassays are an invaluable tool in biomedical research, offering a versatile and cost-effective platform for studying developmental biology, genetics, toxicology, and disease models. These small, tropical fish are particularly advantageous due to their genetic similarity to humans, transparent embryos, and rapid development. Researchers can observe developmental processes in real-time and perform high-throughput screenings of chemical compounds to assess their effects on biological systems. Zebrafish bioassays are instrumental in drug discovery, allowing for the identification of potential therapeutic compounds and the evaluation of their safety and efficacy. Additionally, they are used in environmental science to monitor the impact of pollutants and other environmental factors on living organisms. The ability to conduct large-scale genetic studies and manipulate gene expression in zebrafish further enhances their utility in uncovering various diseases' molecular mechanisms, paving the way for innovative treatments and interventions.

A major challenge in epilepsy research and treatment development is the need for effective and efficient screening methods for anti-epileptic drugs (AEDs). Traditional mammalian models are often time-consuming, costly, and ethically complex. Zebrafish (Danio rerio) have emerged as a promising alternative model for high-throughput screening of AEDs. Through the zebrafish larval locomotive bioassay, house at the Chemistry Department, potential anti-epileptic compounds can be screened. Prior to these activity screenings, toxicity screenings are performed to identify the maximum tolerated concentration of an extract or test compound that is compatible with the larvae.